Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis - Test2 - elhamkhani - TriplyDB

Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis

Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis

http://www.wikidata.org/entity/Q28219355

about

Venous Thromboembolism in Cancer: An Update of Treatment and Prevention in the Era of Newer Anticoagulants Evidence-based case report: multiple thrombotic episodes associated with lenalidomide and dexamethasone therapy for multiple myeloma International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation Thrombosis in multiple myeloma Lenalidomide for the treatment of B-cell lymphoma.Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study.Lenalidomide for the treatment of relapsed and refractory multiple myeloma.Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study Molecular biology for formyl peptide receptors in human diseases.Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)Clinical use of the low-molecular-weight heparins in cancer patients: focus on the improved patient outcomes.Induction therapy and stem cell mobilization in patients with newly diagnosed multiple myeloma.Spectrum of Cerebrovascular Disease in Patients with Multiple Myeloma Undergoing Chemotherapy-Results of a Case Control Study Pharmacokinetics and tissue disposition of lenalidomide in mice.Thrombosis is associated with inferior survival in multiple myeloma.Investigational treatments for multiple myeloma.Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping.The evolving role of lenalidomide in the treatment of hematologic malignancies.Management of venous thromboembolism in patients with cancer: role of dalteparin.Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.Mechanisms of Cardiotoxicity of Cancer Chemotherapeutic Agents: Cardiomyopathy and Beyond.An update on drug combinations for treatment of myeloma.Treatment strategies in myelodysplastic syndromes.Treatment of plasma cell dyscrasias with lenalidomide.Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma.Assessing risk of venous thromboembolism in the patient with cancer.Lenalidomide: a synthetic compound with an evolving role in cancer management.Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement.Guidelines for supportive care in multiple myeloma 2011.Thrombosis in multiple myeloma (MM).Lenalidomide in lymphomas and chronic lymphocytic leukemia.Multiple Myeloma: Cast Nephropathy, VTE, and Neurologic Complications.Comparing venous thromboembolism prophylactic strategies for ambulatory multiple myeloma patients on immunomodulatory drug therapy.Treatment-related symptom management in patients with multiple myeloma: a review.Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myeloma.Increased risk of arterial thromboembolic events with combination lenalidomide/dexamethasone therapy for multiple myeloma.Safety and efficacy of primary thromboprophylaxis in cancer patients.Plasma Thrombin Generation and Sensitivity to Activated Protein C Among Patients With Myeloma and Monoclonal Gammopathy of Undetermined Significance.An unusual cause for an optic disc haemorrhage.

P2860

Q26741697-1E702F09-AE9D-4816-86EA-040D2166C5B2 Q26823292-05082D23-393A-4EFC-9710-05F9EC714772 Q27002668-EDF2FC0F-A7BC-44E1-B1F3-E22CA23108F1 Q28219961-E9B9CB2D-1E79-4C53-9194-EE9B4E08F2DE Q30249007-7CDE64A0-4F8B-4BE5-91BB-9769DF4F8DDA Q33389111-B7A5BC20-151E-4C13-8F90-81409344F914 Q33396036-E0874A25-6625-4FDC-BDC8-F051055DD91A Q33403183-E50D3779-F141-49FD-B15D-E2F5CFD1E932 Q33931754-EEEE1D0E-4131-441A-9F0A-74D07BA73675 Q34327503-455347FA-4DD8-4261-BCA7-3EBD1F130ACF Q34541542-8FD17636-47C8-4ACA-A447-276D4BD36B1E Q35368813-93CE3AE7-EE81-47A0-9118-4B903333AF77 Q36014687-A350F913-4B78-4259-99AF-527570490455 Q36208099-30F28223-286F-4EA5-8C99-6B6303DBFE29 Q36331493-20D0A9E2-0F10-4D39-ADE7-20978644A255 Q36366986-673B94A7-B45E-4CA3-8938-AC5949AE2DB0 Q36654336-F017E537-D4D5-4DAA-9381-A9C7569A479E Q36697556-C2B622B1-FA59-490F-8997-FED659C6B019 Q36739807-9B9004D9-3D5C-45EF-A50E-E3CA1FBF2FC0 Q36812767-63EB3B67-58F1-434B-ACC4-042022C2AA1B Q37038414-90CD2E99-D4AF-4493-B744-42B68D5589D3 Q37038711-1D96A2EA-BCC2-4981-88C4-E9388F4178F8 Q37038973-16124086-6E48-498C-9A0A-17671A5CF709 Q37079916-D2ED1D51-4458-4762-9FF2-04EF23C4611E Q37176044-B6D8A012-E68A-4752-A45A-298E8224611E Q37310407-60ABB8F3-2584-4DF0-B91D-93E7AC77C549 Q37393394-1E368F31-1333-4BE4-A04A-486754B553AA Q37791617-7CEFEB29-FB3E-4C81-B4D5-03E92F0D85DE Q37835695-FC74D8AD-5785-4325-9747-54A0BED42705 Q37868637-58904157-F4BA-468D-B959-5FA165E2E542 Q38003019-9C342853-407B-4FCD-8639-7B3FACE6FA20 Q38077277-D20B863D-8D8F-4647-A279-D85B45FFBBBA Q38230423-8B14197F-5A70-49BB-AA3D-5224DBC234AE Q38336240-8A14691A-7037-4170-AA1C-B1B7B6F7CE53 Q38342281-2BBF82EF-9227-4845-ADFB-CD37B09F319B Q38555091-B2DE4E80-9EC4-4465-9002-8414B6EAAE63 Q38783950-9B42C2C2-7FBB-400F-AF00-D69FC342518B Q38826115-FE7C7A52-4BEB-4A90-9208-1A2500ED56BE Q38921614-F50CA558-54E1-4AA5-93CE-85FCEDB3A3BE Q42702558-C2C26A8F-F673-4789-9776-E1C09695E543

P2860

Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis

http://www.wikidata.org/entity/Q28219355

description

2006 nî lūn-bûn

@nan

2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Thrombotic complications in pa ...... benefit of aspirin prophylaxis

@ast

Thrombotic complications in pa ...... benefit of aspirin prophylaxis

@en

Thrombotic complications in pa ...... benefit of aspirin prophylaxis

@nl

type

label

Thrombotic complications in pa ...... benefit of aspirin prophylaxis

@ast

Thrombotic complications in pa ...... benefit of aspirin prophylaxis

@en

Thrombotic complications in pa ...... benefit of aspirin prophylaxis

@nl

prefLabel

Thrombotic complications in pa ...... benefit of aspirin prophylaxis

@ast

Thrombotic complications in pa ...... benefit of aspirin prophylaxis

@en

Thrombotic complications in pa ...... benefit of aspirin prophylaxis

@nl

P1433

Q28219355-07070926-A8EF-42D7-B824-E82883EDD5EA

P1476

Q28219355-B3827D7B-15C2-4FD8-820C-2E137543B104

P2093

Q28219355-32AB7B69-CB61-49B0-A767-AD54798AEFD1

Q28219355-758898D9-48A0-474F-8CB9-FD4EB9D20B19

Q28219355-90BDE6A6-E9B4-41AC-B574-3425322AC122

Q28219355-A063A1DF-84F1-4619-ADD3-CEBA7B8EADEC

Q28219355-E5130A13-211A-49F5-9CF6-2E339FC01127

P304

Q28219355-F869D611-88EE-40AF-B078-C9F32D80EC2D

P31

Q28219355-A5BD61D4-50C6-488C-9321-3442C21D1F55

P3181

Q28219355-18991FB8-060A-48FB-8469-CD5C8244BFDA

P356

Q28219355-DFF5B8C8-6685-4430-926F-1E18AC14BB00

P407

Q28219355-C5FBA78F-309F-4C35-BD59-8B057BA1D624

P433

Q28219355-9F453FD1-FFD6-49EC-9C7F-D223E21411E1

P478

Q28219355-70391EBF-C0BD-4CC3-A4C6-0FD1CC331264

P50

Q28219355-2FA707D0-EA00-467C-ACD5-5A9616915E29

P577

Q28219355-631BE009-A275-44E2-9784-52F17DFD4C00

P5875

Q28219355-BD875B45-B9A2-47BC-A4CC-FC3EDDECD81A

P698

Q28219355-23577752-C296-4BD2-8803-6D2BF1393475

P921

Q28219355-358D7285-7A26-4507-A0F5-B5EEF1E83B63

Q28219355-7CC90060-CB75-4A97-8383-525A8A7935E7

Q28219355-EE395C23-3D37-4CDE-8D3F-F418CFCE070C

P3181

P356

BLOOD-2006-01-0154

P1433

P1476

Thrombotic complications in pa ...... benefit of aspirin prophylaxis

@en

P2093

Brian G M Durie

http://www.w3.org/2001/XMLSchema#string

Jason McCoy

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Zonder

http://www.w3.org/2001/XMLSchema#string

John Crowley

http://www.w3.org/2001/XMLSchema#string

Mohamad A Hussein

http://www.w3.org/2001/XMLSchema#string

P304

403; author reply 404

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4250274

http://www.w3.org/2001/XMLSchema#string

P356

10.1182/BLOOD-2006-01-0154

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

108

http://www.w3.org/2001/XMLSchema#string

P50

P577

2006-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6993031

http://www.w3.org/2001/XMLSchema#string

P698

16790586

http://www.w3.org/2001/XMLSchema#string

P921